March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant
zwyiLGP-_400x400

Final results of the phase I/IIa clinical trial (NCT02253212) on the ultrasound-induced blood-brain barrier (BBB) opening improving the efficiency of carboplatin chemotherapy for recurrent glioblastoma patients were published in AACR’s Clinical Cancer Research journal of the . Study results show a good safety profile and encouraging efficacy. These results are based on 65 sonication sessions […]

Read more »
March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant
  • unnamed-2
    unnamed-3

     
  • News CarThera

    25.06.2019
    June 2019: CarThera appoints Pascal E. R. Girin as chairman of board of directors

    Pascal Girin brings wealth of experience in medical device and life sciences industries to support CarThera’s future growth. Girin has decades of business expertise in the life sciences and medical devices markets, most recently as CEO of Balt, a leader in the treatment of neurovascular diseases. Prior to this, he held numerous C-level positions at leading medical companies, including Wright Medical, Keystone Dental (a Warburg Pincus company), EV3, Baxter and Ohmeda, among others. As chairman of CarThera’s board of directors, he will bring invaluable insight to the company’s business strategy and future development.

    25.06.2019
    March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant

    Final results of the phase I/IIa clinical trial (NCT02253212) on the ultrasound-induced blood-brain barrier (BBB) opening improving the efficiency of carboplatin chemotherapy for recurrent glioblastoma patients were published in AACR’s Clinical Cancer Research journal of the . Study results show a good safety profile and encouraging efficacy. These results are based on 65 sonication sessions with escalating ultrasound pressure levels. GBM patients treated with optimal pressure levels and MRI-detected disrupted BBB (11 patients) showed a median progression-free survival (PFS) of 4.11 months and a median overall survival (OS) of 12.94 months. This compares to 2.73 months and 8.64 months respectively, for GBM patients without BBB disruption (8 patients).

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.

  • Category Archives: Uncategorized

    zwyiLGP-_400x400

    Final results of the phase I/IIa clinical trial (NCT02253212) on…

    Read more »
    LogosFonds

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners,…

    Read more »
    ASCO2018

    Preliminary data from the first clinical trial of the company’s…

    Read more »
    logoBIO2018Small

    CarThera will participate to the BIO International Convention in Boston…

    Read more »
    ASCO

    June 2017 – Dr. Ahmed Idbaih, AP-HP principal investigator of…

    Read more »
    bpifrance-logo

    October 12, 2016 – CarThera has received a grant of…

    Read more »
    Science

    SonoCloud® uses ultrasound to achieve permeability of blood vessels in…

    Read more »
    Remises Awards Biovision 2016

    The Investor Conference of Biovision is a unique opportunity for…

    Read more »
    QDM220615

    “Destroying complex shape tumors using MR guided ultrasound probes, opening the Blood-Brain Barrier with…

    Read more »
    HirshCarpentier

    Annual day of the Technology Transfert Department of APHP (Assistance…

    Read more »